AstraZenca Pharma India
ASTRAZEN
AstraZenca Pharma India Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 42,891 |
| Weekly | 11.09% | 7,32,228 |
| Monthly | 10.30% | 16,89,319 |
AstraZenca Pharma India Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| ASTRAZEN | - | 11.09% | 10.30% |
| Index | - | - | - |
| Peer Avg. | -0.01% | 1.01% | 2.14% |
AstraZenca Pharma India Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| ASTRAZEN | 103.71 | 12.54 | 58.89 | 12.78 | 17.36 | 0.28 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 35.31 | 3.95 | 12.55 | 16.53 | 7.42 | 2.36 |
AstraZenca Pharma India Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | -0.98% | -33.98% | 12.78% | 17.36% |
| FY '20-21 | -2.19% | 29.21% | 22.83% | 31.24% |
| FY '19-20 | 14.21% | 32.62% | 21.83% | 34.61% |
AstraZenca Pharma India Shareholding Pattern
AstraZenca Pharma India Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 805.60 | 719.42 | 100.94 | 61.60 |
| FY '20-21 | 813.56 | 678.09 | 148.31 | 93.30 |
| FY '19-20 | 831.81 | 711.11 | 133.69 | 72.21 |
AstraZenca Pharma India Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| ASTRAZEN | 805.60 | 719.42 | 100.94 | 61.60 |
| KARURVYSYA | 5,587.67 | 5,425.81 | 930.92 | 673.27 |
| HUDCO | 6,954.42 | 361.18 | 6,886.37 | 1,716.60 |
AstraZenca Pharma India Share Price
AstraZeneca Pharma India Limited is an Indian biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolic; oncology and respiratory diseases. The company operates through the healthcare segment. The company manufactures, markets and distributes pharmaceuticals and provides clinical research services to a foreign group company. Its therapeutic offering in the CVRM business includes Forxiga (Dapagliflozin) in heart failure and chronic kidney disease. Its approvals in the oncology business include Imfinz (Durvalumab) for the treatment of bile duct carcinoma and Lynparza (Olaparib) for early breast cancer. The company has a range of oral diabetes medications that fall into two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The company's DPP4 offering consists of the Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metform) brands.